Table 3 Endoscopic Changes Post-taVNS Therapy: Retrospective Review
Study Subject | Diagnosis | Disease location | Pre-study Endoscopic disease severity | Medication at study entry | Duration of taVNS (weeks) | Follow up endoscopic disease severity | Clinical outcome |
|---|---|---|---|---|---|---|---|
6 | CD | Right colon | SES-CD = 4 | None | 69 | SES-CD = 3 | Continued taVNS started UST |
7 | CD | Left colon | SES-CD = 6 | Mesalamine | 60 | SES-CD = 2 | Continued taVNS |
8 | CD | Left colon | SES-CD = 10 | VDZ | 16 | SES-CD = 4 | Continued taVNS |
9 | UC | Pancolonic | Mayo score 2 | Mesalamine | 21 | Mayo score 2 | Discontinued taVNS started VDZ |